Design, synthesis, and biological evaluation of novel pyrido[2,3-d]pyrimidines containing derivatives

International Journal of Applied Chemistry

© 2019 by SSRG - IJAC Journal

Volume 6 Issue 3

Year of Publication : 2019

Authors : Hemanshu Thakorbhai. Tandel

10.14445/23939133/IJAC-V6I3P112

How to Cite?

Hemanshu Thakorbhai. Tandel, "Design, synthesis, and biological evaluation of novel pyrido[2,3-d]pyrimidines containing derivatives," SSRG International Journal of Applied Chemistry, vol. 6,  no. 3, pp. 92-98, 2019. Crossref, https://doi.org/10.14445/23939133/IJAC-V6I3P112

Abstract:

We have synthesized some new pyrido[2,3-d]pyrimidines containing some imines and 4- thiazolidinone derivatives by applying standard Vilsmeier-Haack reaction condition, reaction of N-(2,6-dimethoxypyrimidin-4-yl)acetamide (2) with Vilsmeier-Haack reagents gives 7-chloro-2,4 - dimethoxy pyrido[2,3-d]pyrimidine-6-carbaldehyde (3) which on further react with morpholine (4) and various substituted heteroamines (6a-d) gives 2,4- dimethoxy-7-morpholinopyrido[2,3-d] pyrimidine-6-carbaldehyde (5) and substituted Schiff bases (7a-d) respectively. Finally the reaction of various Schiff bases (7a-d) with thioglycolic acid and thiolactic acid gives 2,3-disubstituted-4-thiazolidinone (8a-d) and 2,3-disubstituted-5-methyl-4-thiazolidinone (9ad) derivatives respectively. The best reaction condition for this goal was achieved by using acidic reaction condition. The salient features of this reaction are (1) it tolerates a wide range of functional groups, (2) easy to handle and required mild reaction conditions. Synthesized and
characterised by elemental analyses and spectroscopic techniques. Stirred from literature survey of COX-1 and COX-2 enzyme inhibition study we establish that benzothiazole type structure is more suitable to inhibit concentration of COX-1 and COX-2 enzymes and to testing in vitro COX-1 and COX-2 inhibition study for synthesised derivatives. This study identified the potential compounds, which can be capable leads for their subsequent development as newer anti-inflammatory agents.

Keywords:

pyrido[2,3-d]pyrimidines, COX-1/COX-2 inhibition activity, Vilsmeier-Haack reaction.

References:

[1] Q. Zhuang, X. Wang, Y. Gao, F. Shi, B. Jiang, S. Tu, ACS. Comb. Sci., 2011, 13, 84–88.
[2] A. C. Tripathi, S. J. Gupta, G. N. Fatima, P. K. Sonar, A. Verma, S. K. Saraf, Eur. J Med Chem., 2014, 24 (72), 52-77.
[3] W. Witte, J. Antimicrob. Chemother. 1999, 44A, 1.
[4] W.L. Smith, R. Langenbach, J Clin Invest.,2001, 107, 1491.
[5] N. Ghosh, R. Chaki, V. Mandal, S.C. Mandal, Pharmacol. Reports., 2010, 62, 233.
[6] C. Charlier, C. Michaux, Eur. J. Med. Chem., 2003, 38, 645.
[7] Y. Engin, O. Sa, S.K. Fatma, K. Erol, Infalmmation., 2013,36,476.
[8] B. Sever, M. Ozkurt, A. Ozdemir, Eur. J. Med. Chem., 2016, 113, 179.
[9] A. Bali, R. Ohri, P.K. Deb, Eur. J. Med. Chem., 2012, 49, 397.
[10] M. A. Baseer, V. D. Jasdhav, R. M. Phule, Y. V. Archana, Y. B. Vibhute, Orient. J. Chem., 2000, 16, 553.
[11] Aboul-Fadl, T.; Bin-Jubair, F.A.; Aboul-Wafa, O.; Eur. J. Med. Chem.2010, 45, 4578.
[12] Jarrahpour, A.; Shirvani, P.; Sharghi, H.; Aberi, M.; Sinou, V.; Latour, C.; Brunel, J.M.; Med. Chem. Res., 2015, 24, 4105.
[13] Sridhar, S.K.; Pandeya, S.N.; De Clercq, E.; Boll. Chim. Farm, 2001,140, 302.
[14] T. Aboul-Fadl, F. A. Bin-Jubair, O. Aboul-Wafa, Eur. J. Med. Chem.,2010, 45, 4578.
[15] A. Jarrahpour, P. Shirvani, H. Sharghi, M. Aberi, V. Sinou, C. Latour, J. M. Brunel, Med. Chem. Res., 2015, 24, 4105.
[16] A. C. Tripathi, S. J. Gupta, G. N. Fatima, P. K. Sonar, A. Verma, S. K. Saraf, Eur. J. Med. Chem., 2014, 72, 52-77.
[17] A. Taranalli, A. Bhat, S. Srinivas, E. Saravanan, Ind. J. Pharm. Sci., 2008, 70 (2), 159-164.
[18] N. Karalı, A. Gürsoy, F. Kandemirli, N. Shvets, F. B. Kaynak, S. Özbey, V. Kovalishyn, A. Dimoglo, Bioorg. Med. Chem.,2007, 15 (17), 5888-5904.
[19] D. Kaminskyy, B. Bednarczyk-Cwynar, O. Vasylenko, O. Kazakova, B. Zimenkovsky, L. Zaprutko, R. Lesyk, Med. Chem. Res., 2012, 21 (11), 3568- 3580.
[20] D. Havrylyuk, B. Zimenkovsky, O. Vasylenko, A. Gzella, R.J. Lesyk, Med. Chem., 2012, 55 (20), 8630-8641.
[21] J. Balzarini, B. Orzeszko-Krzesińska, J. K. Maurin, A. Orzeszko, Eur. J. Med. Chem., 2009, 44 (1), 303-311.
[22] V. S. Palekar, A. J. Damle, S. R. Shukla, Eur. J. Med. Chem., 2009, 44 (12), 5112- 5116.
[23] K. Omar, A. Geronikaki, P. Zoumpoulakis, C. Camoutsis, M. Soković, A. Ćirić, Glamočlija, J. Bioorg. Med. Chem., 2010, 18 (1), 426-432.
[24] N. Terzioğlu, N. Karalıa, A. Gürsoy, C. Pannecouque, P. Leysenb, J. Paeshuyseb, J. Neyts, De Clercq, E. Arkivoc., 2006, 1, 109-118.
[25] F. Ragab, N.M. Eid, H. El-Tawab, Pharmazie., 1997, 52 (12), 926-929.
[26] D. Raikwar, S. Srivastava, S. Srivastava, J. Indian Chem. Soc., 2008, 85 (1), 78-84.
[27] A. Srinivas, A. Nagaraj, C. S. Reddy, J. Heterocycl. Chem., 2008, 45 (4), 999-1003.
[28] M. V. Diurno, O. Mazzoni, E. Piscopo, A. Calignano, F. Giordano, A. Bolognese, J. Med. Chem., 1992, 35 (15), 2910-2912.
[29] C. Praveen, A. N. Kumar, P. D. Kumar, D. Muralidharan, P. T. Perumal, J.Chem.Sci., 2012, 124, 609-624.
[30] G. Mariappan, P. Prabhat, L. Sutharson, J. Banerjee, U. Patangia, S. Nath, J. Korean Chem. Soc., 2012, 56, 251-256.
[31] K. N. Venugopala, M. Krishnappa, S. K. Nayak, B. K. Subrahmanya, J. P. Vaderapura, R. K. Chalannavar, R.M. Gleiser, B. Odhav, Eur. J. Med. Chem., 2013, 65, 295-303.
[32] S. Bondock, W. Fadaly, M. A. Metwally, Eur. J. Med. Chem., 2010, 45, 3692-3701.
[33] C. Pittenger, V. Coric, M. Banasr, M. Bloch, J. H. Krystal,G. Sanacora, CNS Drugs,2008, 22,761-786.
[34] J. Sporn, S. N. Ghaemi, M. R. Sambur, M. A. Rankin, J. Recht, G. S. Sachs, J. F. Rosenbaum, M. Fava, Ann. Clin. Psychiatry, 2000, 12, 137-140.
[35] I.A. Al-suwaidan, A.M. Alanazi, A.S. El-azab, A.M. Alobaid, K.E.H. Eltahir, A.R. Maarouf, M.A.A. El-enin, A.A. Abdel-aziz, Bioorg. Med. Chem. Lett., 2013, 23,2601.
[36] A.A. Abdel-aziz, A.S. El-azab, L.A. Abou-zeid, K. Eldin, H. Eltahir, N.I. Abdel-aziz, R.R. Ayyad, A.M. Al-obaid, Eur. J. Med. Chem., 2016, 115, 121.